RecallRadar

FDA Drug recall D-0226-2017

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactu…

On 2016-12-28 the FDA classified a Class II recall of AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactu… by Amgen, citing lack of Assurance of Sterility: Potential cracks in glass vials.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0226-2017
ClassificationClass II
Statusterminated
Initiated2016-12-15
Published2016-12-28
Last updated2026-09-13 11:51 UTC
CompanyAmgen
DistributionPR

Product

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01

Reason

Lack of Assurance of Sterility: Potential cracks in glass vials

Identifiers

ndc76075-101-01
ndc76075-101-21
ndc76075-102-01
ndc76075-102-21
ndc76075-103-01
ndc76075-103-21
code_infoLot #1071559, 1071629; Exp. 05/18

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0226-2017%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.